Sovicell microsomal kit
TRANSIL Metabolic Bias Kit
  • Load image into Gallery viewer, Sovicell microsomal kit
  • Load image into Gallery viewer, TRANSIL Metabolic Bias Kit

TRANSIL Metabolic Bias Kit

€651.00
€651.00
Sold out

Correct Metabolic Rate Bias in Microsomal and Hepatocyte Stability Assays

Rapid measurement of membrane binding to calculate fu(mic) and fu(hepatocyte) and correct intrinsic clearance estimates.

Membrane Binding Distorts Metabolic Stability Data

In microsomal and hepatocyte stability assays it is often assumed that the total drug concentration is available for metabolism. In reality, many compounds bind extensively to intracellular membranes such as the endoplasmic reticulum, mitochondria, or plasma membrane.

This reduces the unbound drug concentration available to metabolic enzymes and leads to systematic underestimation of intrinsic clearance.

For example, a compound with fu = 0.01 will produce an apparent clearance that is 100-fold lower than the true intrinsic clearance. This bias can lead to incorrect compound ranking, misleading IVIVE predictions, and inaccurate assessment of drug–drug interaction risk.

The TRANSIL Metabolic Bias Assay

The TRANSIL Metabolic Bias Assay measures the membrane affinity of a compound using immobilized biological membranes. From this affinity, the unbound fraction in microsomal or hepatocyte incubations can be calculated for any experimental condition. Because membrane affinity is an intrinsic physicochemical property of the compound, the measurement can be used to correct metabolic stability assays across different protein concentrations or cell densities.

Unlike dialysis-based binding assays, the TRANSIL approach determines membrane affinity within minutes and avoids compound degradation or solubility artifacts that often occur during long equilibrium incubations.

Key advantages:

  • Rapid 12-minute incubation
  • No enzymatic degradation during measurement
  • Direct compatibility with LC-MS workflows
  • Applicable to both microsomes and hepatocytes

Why Correcting Metabolic Bias Matters

Accurate estimation of intrinsic clearance is essential for predicting human pharmacokinetics and selecting the best drug candidates during lead optimization. In microsomal or hepatocyte stability assays, however, many compounds bind extensively to intracellular membranes, which reduces the unbound drug concentration available for metabolism. If this effect is not corrected, the measured metabolic rate reflects the total concentration rather than the biologically relevant free concentration, leading to systematic underestimation of intrinsic clearance. Correcting for membrane binding therefore improves compound ranking, strengthens in vitro–in vivo extrapolation (IVIVE), and provides more reliable estimates of drug–drug interaction risk by ensuring that metabolic turnover and inhibition are interpreted based on the true unbound drug concentration.

The TRANSIL Approach

The TRANSIL Metabolic Bias Kit quantifies membrane binding using Sovicell’s established TRANSIL membrane affinity technology. In this assay, biological membranes are immobilized on silica beads and incubated with the test compound at several defined membrane surface densities. The compound partitions between the aqueous phase and the immobilized membrane phase according to its intrinsic membrane affinity. Because membrane affinity is a physicochemical property of the compound, the measurement can be used to calculate unbound fractions across a wide range of experimental conditions.

After a short incubation, the beads are separated by centrifugation and the remaining compound concentration in the supernatant is quantified using standard analytical methods such as LC-MS/MS or HPLC-UV. From the change in supernatant concentration across increasing membrane levels, the membrane affinity of the compound is determined and used to calculate the unbound fraction in microsomal or hepatocyte incubations (fu) under the conditions used in metabolic stability assays. This enables straightforward correction of intrinsic clearance estimates for membrane binding bias.

How the Assay Works

The assay determines microsomal and hepatocyte membrane binding through the following equilibrium partitioning workflow:

  1. Compound is added to wells containing increasing amounts of membrane- coated beads
  2. Compound partitions between membrane and aqueous phase
  3. Supernatant concentration is quantified
  4. Membrane affinity is calculated
  5. fu(mic) or fu(hepatocyte) is derived for the desired assay conditions

Cross-Species Applicability

The membrane affinity measured with the TRANSIL Metabolic Bias Kit reflects the intrinsic partitioning of a compound into biological lipid membranes. Because the basic architecture and lipid composition of cellular membranes are highly conserved across mammalian species, membrane affinity is largely independent of the species from which microsomes or hepatocytes are derived. Studies of liver microsomes have shown that the relative proportions of the major phospholipids—such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and sphingomyelin—as well as the cholesterol-to-phospholipid ratio are very similar between species including human and rat.

As a result, the membrane affinity determined in the TRANSIL assay can be used to estimate unbound fractions in microsomal or hepatocyte incubations from different preclinical species. By combining the measured membrane affinity with species- specific parameters such as microsomal protein concentration or hepatocyte density, the supplied analysis tools allow prediction of fu(mic) and fu(hepatocyte) under the experimental conditions used in metabolic stability studies.

Features and Benefits

  • Direct measurement of membrane affinity

    Determines the intrinsic partitioning of compounds into biological membranes, enabling calculation of the unbound fraction in microsomal and hepatocyte incubations.

  • Correction of intrinsic clearance estimates

    Allows accurate correction of metabolic stability data by accounting for membrane binding, improving the reliability of intrinsic clearance calculations.

  • Applicable to both microsomes and hepatocytes

    One measurement can be used to calculate fu(mic) and fu(hepatocyte) under different experimental conditions, supporting a wide range of metabolic stability assays.

  • Rapid 12-minute incubation

    Provides fast results without the long equilibration times required for dialysis- based binding assays.

  • No risk of metabolic degradation during measurement

    Because the assay does not require long incubations with active enzymes, compound degradation does not confound binding measurements.

  • Ready-to-use 96-well plate format

    Enables straightforward integration into standard ADME workflows and allows up to 12 compounds per plate.

  • Compatible with standard analytical methods

    Supernatants can be quantified using LC-MS/MS, HPLC-UV, scintillation counting, or other detection technologies.

  • Automation-friendly workflow

    The plate format and short protocol are compatible with liquid handling systems used in high-throughput screening environments.

  • Quantitative data analysis with built-in QC metrics

    The supplied analysis spreadsheet calculates membrane affinity, unbound fractions, and quality parameters to ensure reliable results.

  • Supports improved IVIVE and DDI prediction

    More accurate unbound drug estimates strengthen pharmacokinetic predictions and improve the assessment of drug–drug interaction risk.

  • How comparable are the results of the TRANSIL Microsomal Binding kit to dialysis?

    Choosing a diverse compound set of 22 drugs we observed a strong correlation (r2=0.97) between the results from the ready-to-use TRANSIL kits and dialysis with microsomal homogenates. This indicates that the methods are highly comparable and validates the assumption that microsomal binding is attributable to membrane binding alone.

  • How comparable are the results of the TRANSIL Microsomal Binding kit to literature data and QSAR predictions?

    Comparing a set of 6 drugs with reported literature values for fu mic that were obtained by dialysis with microsomal homogenates and results from the ready-to-use TRANSIL kits we observed strong correlation with an r2 of 0.88, however, when comparing the experimental data to quantitative structure-activity relationship model predictions the correlation deteriorates down to an r2 of 0.66. In fact, the Austin model consistently underpredicts fu mic while the Turner as well as Halifax & Houston models have less systematic bias but still low precision.

    fu mic experimental fu mic QSAR
    Drug TRANSIL Literature Cp [mg/ml] Poulin Halifax & Houston Turner et al. Austin et al.
    Diazepam 86% 75% 0.5 91% 81% 75% 55%
    Alprazolam 66% 66% 5 90% 51% 45% 29%
    Midazolam 74% 88% 1 34% 37% 34% 14%
    Propranolol 41% 50% 1 48% 42% 41% 17%
    Triazolam 85% 78% 1 93% 76% 69% 50%
    Warfarin 100% 100% 0.1 100% 99% 99% 99%

  • Why is it important to measure microsomal and hepatocyte binding?

    Subcellular fractions such as liver microsomes are useful in vitro models for investigation of hepatic clearance and drug-drug interactions. However, it is the unbound substrate or inhibitor concentration which is important in the prediction of in vivo pharmacokinetics as only the free drug can interact with drug metabolizing enzymes in the microsomal incubations. Knowledge of the extent of microsomal binding leads to a better understanding of the relationship between in vitro metabolism and in vivo pharmacokinetics.

    • Clearance may be underpredicted if fu mic is ignored
    • QSAR models predict fu mic poorly
    • Interpretation of drug-drug interaction data can be affected by fu mic as inhibitor potency can be underestimated

  • Why is microsomal binding important in prediction of clearance from in vitro microsomal clearance incubations?

    Only the free unbound compound is available to be metabolized by the enzymes present in microsomal incubations. Therefore, it is important to consider the extent of binding when performing microsomal clearance studies. Several studies show that correcting for non-specific microsomal binding improves the prediction of in vivo clearance (Carlile et al. 1999, Obach 1997, 1999).

  • Can I use the results from the TRANSIL Microsomal Binding kit also for estimating hepatocyte binding?

    Yes, the TRANSIL Microsomal Binding Kit can also be used to estimate hepatocyte binding because it determines the affinity of test items to liver microsomal membranes and they differ only marginally in their composition to hepatocyte membranes.

  • What does the TRANSIL Microsomal Binding kit measure?

    The TRANSIL Microsomal Binding Kit measures the affinity of a test item to immobilized microsomal membranes with natural membrane fluidity. This membrane affinity is a partitioning coefficient of drug between membrane and buffer. It is defined as the concentration of drug in membrane (cl) over the concentration of drug in buffer (cb):

    The membrane affinity is calculated from the assay data using the mass balance equation:

    which is rearranged such that the membrane affinity can be determined from the slope of plotting the ratio of total amount of drug (nt) over remaining concentration in supernatant (cb) against the lipid membrane volume present in each well:

  • What positive and negative control is used in the assay?

    We recommend fluoxetine as positive control and warfarin as negative control.

  • What are the main quality control measures applied in TRANSIL assays?

    The TRANSIL Quality Index (TQI) is based on independent measures derived from the data analysis.

    • Model fit (see equation 3 of the section “how the assay works”
    • Recovery: does the model derived compound concentration equal the true concentration?
    • Data consistency: does membrane binding increase proportionally with the increasing TRANSIL bead content in each well?
    • Data consistency: are the estimated reference concentrations in alignment with the compound concentration used?
    • Missing data and outliers.

  • How long does it take to run the assay?

    One assay plate can be used for 12 compounds. Thus, you’ll need to pipette 15 µl of test item to each of 8 wells and repeat this for all 12 compounds. This takes less than 10 minutes even with manual pipetting. After compound addition, the plate is ready for incubation. You can do this with an electronic 8 or 12 channel pipette by aspirating and dispensing a volume of 120 µl for 15 times. That takes just over a minute for each column or row. In total, that makes 8 to 15 minutes depending on your pipette. When using a pipetting robot with a 96 well head this time decreases to 2 minutes. After incubation, the plate needs to be spun in a plate centrifuge for 10 minutes. The supernatants are then ready for quantification by LC/MS/MS, UV, fluorescence or any other method of your choice.

    Thus, the total time the start and end of the experiment varies between 7 and 25 minutes depending upon your equipment.

  • How many compounds can be analyzed with one plate?

    One assay plate can be used for 12 compounds. A special feature of the 96 well plates used for these kits is that each of the 12 columns can be separated from the plate. Thus, it is possible to use the plate for one compound at a time.

  • Are TRANSIL assay kits supplied in low-binding plates?

    The TRANSIL assay kits utilize Micronic 96 well plates with ultra-low-binding tubes. Standard polypropylene tubes have 41x higher non-specific binding and low-binding tubes from other vendors have 2.6x higher non-specific binding.